STAAR Surgical Overhauls Board as Broadwood Partners Gain Influence
Event summary
- Broadwood Partners, owning 31% of STAAR Surgical, adds three directors to the board, including its founder Neal Bradsher.
- STAAR Chair Elizabeth Yeu and CEO Stephen Farrell step down from the board; Farrell remains CEO until January 31, 2026.
- Board expands from six to seven members, with plans to announce new Chair and CEO soon.
- Broadwood agrees to standstill provisions as part of the cooperation agreement.
The big picture
STAAR Surgical’s board overhaul reflects Broadwood Partners’ growing influence as its largest shareholder. The move comes amid a push for enhanced profitability and sustainable growth, following a period of financial recovery. The strategic shift underscores the importance of investor-backed governance in the medical device sector, particularly for companies with niche, high-growth products like phakic IOLs.
What we're watching
- Governance Dynamics
- How Broadwood’s increased board presence will impact STAAR’s strategic direction and operational decisions.
- Leadership Stability
- Whether the interim CEO arrangement will lead to a smooth transition or create operational uncertainty.
- Profitability Focus
- The pace at which the new board can drive profitability and long-term value creation.
Related topics